胱抑素C与需持续肾脏替代治疗急性肾损伤患者的肾功能恢复
本研究为回顾性观察研究,纳入72例需持续肾脏替代治疗(CKRT)的急性肾损伤(AKI)患者,分析CKRT启动前及第1、2、3天血浆胱抑素C水平与肾功能恢复的关系。结果发现早期肾功能恢复者第1、2、3天血浆胱抑素C显著低于延迟恢复者,第1-3天最低值可预测早期恢复(AUC 0.77,P=0.002)。
要点
- 早期恢复者CKRT第1、2、3天血浆胱抑素C显著低于延迟恢复者。
- 第1-3天最低血浆胱抑素C预测早期恢复的AUC为0.77(P=0.002)。
- 血浆胱抑素C<1.30 mg/L时阳性似然比5.60,≥1.88 mg/L时阴性似然比0.17。
核心结论
- CKRT前3天较低的血浆胱抑素C浓度与早期肾功能恢复相关。
研究设计与样本
- 回顾性观察研究,从126例单中心CKRT研究中纳入72例患者。
- 预设两个队列:早期恢复(CKRT启动7天内脱离KRT)与延迟恢复(KRT>21天或死亡)。
- 检测CKRT启动前及第1、2、3天储存的血浆、尿液和透析流出液中胱抑素C。
主要发现
- 早期恢复者第1天血浆胱抑素C为1.79 vs 2.39 mg/L,第2天1.91 vs 2.38 mg/L,第3天2.04 vs 2.67 mg/L,均显著低于延迟恢复者。
- 早期与延迟恢复者的胱抑素C筛分系数和CKRT清除率相似。
- 第1-3天最低血浆胱抑素C预测早期恢复的AUC为0.77(P=0.002)。
- 血浆胱抑素C<1.30 mg/L时阳性似然比为5.60,≥1.88 mg/L时阴性似然比为0.17。
临床怎么用
- CKRT期间血浆胱抑素C仍可能作为预测AKI患者肾功能恢复的临床工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Plasma cystatin C is decreased in participants with AKI requiring continuous KRT (CKRT) with early kidney function recovery. Despite being cleared by CKRT, plasma cystatin C in the first 3 days of CKRT may be a useful clinical tool to help predict the prognosis of AKI requiring CKRT. BACKGROUND: Plasma cystatin C is a reliable marker to estimate kidney function; however, it is unknown whether this remains true in patients receiving continuous KRT (CKRT). In this study, we tested the hypothesis that lower concentrations of plasma cystatin C during the first 3 days of CKRT would predict kidney function recovery. METHODS: We performed a retrospective observational study of 72 patients from a 126-patient, single-center CKRT study. We studied two a priori defined cohorts of patients without advanced CKD who had AKI requiring CKRT: (1) with early kidney function recovery defined as liberation from KRT within 7 days of CKRT initiation versus (2) with delayed kidney function recovery defined as receipt of KRT for >21 days or death while on KRT. Subsequent analysis included patients with advanced CKD and intermediate kidney function recovery (liberation between 8 and 21 days). Cystatin C was then measured on stored plasma, urine, and dialysis effluent collected before CKRT initiation and on days 1, 2, and 3 of CKRT. RESULTS: Plasma cystatin C was significantly lower in patients with early kidney function recovery in comparison with patients with delayed kidney function recovery on days 1 (1.79 versus 2.39 mg/L), 2 (1.91 versus 2.38 mg/L), and 3 (2.04 versus 2.67 mg/L) of CKRT. Sieving coefficient and CKRT clearance of cystatin C were similar for patients with early and delayed kidney function recovery. The lowest plasma cystatin C concentration on days 1–3 of CKRT predicted early kidney function recovery with an area under the receiver operating curve of 0.77 (P=0.002), positive likelihood ratio of 5.60 for plasma cystatin C <1.30 mg/L, and negative likelihood ratio of 0.17 for plasma cystatin C ≥1.88 mg/L. CONCLUSIONS: Lower plasma cystatin C concentrations during the first 3 days of CKRT are associated with early kidney function recovery.
引用
- Haeger SM, Okamura K, Li AS, et al. Cystatin C and Kidney Function Recovery in Patients Requiring Continuous KRT for Acute Kidney Injury. Clin J Am Soc Nephrol. 2024. PMID: 39167447. doi:10.2215/CJN.0000000000000531
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。